Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis
This trial is active, not recruiting.
|Condition||amyotrophic lateral sclerosis|
|Sponsor||Centre Hospitalier Universitaire de Nīmes|
|Start date||March 2014|
|End date||June 2017|
|Trial size||800 participants|
|Trial identifier||NCT02893605, AOI/2014/KM-01|
This is a case-control study performed on a biological collection. The polymorphisms present on a pre-defined list of genes will be studied for 400 Amyotrophic Lateral Sclerosis (sporadic type) DNA samples and 400 control DNA samples.
|Observational model||case control|
Patients have a sporadic form of Amyotrophic Lateral Sclerosis.
Controls correspond to spouses/partners of patients.
The polymorphisms occurring on a pre-defined set of genes
time frame: Day 0 (transversal study)
Male or female participants of any age.
Inclusion Criteria: - The primary inclusion criterium is the same for that of the parent biological collection, i.e. the patients fulfill requirements for probable or definite Amyotrophic Lateral Sclerosis as defined by revised international criteria (Brooks et al 2000). - Additionally, included patients were followed-up by doctors at the University Hospital of Montpellier, thus enabling verification of Amyotrophic Lateral Sclerosis criteria over time. Exclusion Criteria: - The patient has a familial form of Amyotrophic Lateral Sclerosis (autosomic dominant or recessive types) with or without a mutation of one of the 3 genes known to be responsible for familial forms (SOD1, TARDBP, FUS). See Bender (1998).
|Official title||Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis|
|Principal investigator||Kevin Mouzat, MD, PhD|
Call for more information